1.66
-0.01 (-0.60%)
| Penutupan Terdahulu | 1.67 |
| Jumlah Dagangan | 3,493,695 |
| Harga / Jualan (P/S) | 0.600 |
| Harga / Buku (P/B) | 0.190 |
| Julat 52 Minggu |
| Margin Keuntungan | 728.88% |
| Margin Operasi (TTM) | -1,098.54% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 236.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 20.91% |
| Nisbah Semasa (MRQ) | 1.32 |
| Aliran Tunai Operasi (OCF TTM) | -6.33 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.82 M |
| Pulangan Atas Aset (ROA TTM) | -34.92% |
| Pulangan Atas Ekuiti (ROE TTM) | 177.37% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Scinai Immunotherapeutics Ltd. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.81 |
|
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai’s drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 18.22% |
| % Dimiliki oleh Institusi | 26.55% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |